Dana Monroe on Yervoy Side Effect Nurse Self-Education

Pembrolizumab led to improved survival over ipilimumab in patients with unresectable advanced melanoma, according to long-term data.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Tumor sizes reduced from treatment with VP-315 in patients with basal cell carcinoma.

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.

The resubmission of the biologics license application for cosibelimab for locally advanced or metastatic cutaneous squamous cell carcinoma follows a complete response letter from the FDA in December 2023.